靶向药物治疗提升了HER2阳性乳腺癌患者的生存率,基于HER2等分子标记的预后预测及药物响应评估技术成为推动HER2阳性肿瘤精准医学持续发展的因素之一。本文梳理了HER2分子标记与预后预测、药物开发、药物响应评估、联合用药方案研究的国内外专利技术进展,以期为促进我国HER2阳性肿瘤个体化靶向治疗的发展提供参考。 Targeted drug therapy enhances the survival rate of patients with HER2-positive breast cancer. The prognosis prediction and drug response evaluation based on HER2 and other molecular markers have become one of the factors contributing to the continuous development of precision medicine for HER2-positive tumors. In this paper, we reviewed the progress of patented technologies both at home and abroad in HER2 molecular marker and prognosis prediction, drug development, drug response evaluation and combination drug regimen, in order to provide a reference for promoting the development of personalized targeted therapy of HER2 positive tumors in our country.